Page 175 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Supplementary Table 5. Overview of participating centers in this study
Supplement
Center
Erasmus Medical Center, Rotterdam, the Netherlands
The Netherlands Cancer Institute, Amsterdam, the Netherlands
Catharina Hospital, Eindhoven, the Netherlands
Leiden University Medical Center, Leiden, the Netherlands
Hospital Gelderse Vallei, Ede, the Netherlands Reinier de Graaf Hospital, Delft, the Netherlandsa
Haaglanden Medical Center, the Hague, the Netherlands
Deventer Hospital, Deventer, the Netherlands Haga Hospital, the Hague, the Netherlandsa
Maastricht University Medical Center, Maastricht, the Netherlands
Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands
Amphia Hospital, Breda, the Netherlands
Bravis Hospital, Roosendaal, the Netherlands University Medical Center, Utrecht, the Netherlands
Wilhelmina Hospital, Assen, the Netherlands Laurentius Hospital, Roermond, the Netherlands
Canisius-Wilhelmina Hospital, the Netherlands
Principal investigator Number of eligible patients
included
Prof. Ron H.J. Mathijssen, 264 MD
Prof. Jan H.M. Schellens, 210 MD
Geert-Jan Creemers, MD 118
Prof. Hans Gelderblom, 93 MD
Arnold Baars, MD 88
Vincent O. Dezentjé, MD / 79 Annelie J.E. Vulink, MD
Frank J.F. Jeurissen, MD 46
Alexander L.T. Imholz, MD 41
Prof. Johanna E.A. 35 Portielje, MD / Danny Houtsma, MD
Rob L.H. Jansen, MD 28 Paul Hamberg, MD 24
Albert J. ten Tije, MD 20
Helga J. Droogendijk, MD 17
Prof. Miriam Koopman, 14 MD
Peter Nieboer, MD 13
Marlène H.W. van de Poel, 9 MD
Caroline M.P.W. 4 Mandigers, MD
5
a In these centers the principal investigator was switched during the study.
173